BioCentury
ARTICLE | Clinical News

Mylan gets first FDA approval for an Advair generic

February 1, 2019 1:15 AM UTC

FDA approved Wixela Inhub salmeterol/fluticasone from Mylan N.V. (NASDAQ:MYL), the first generic version of Advair salmeterol/fluticasone from GlaxoSmithKline plc (NYSE:GSK; LSE:GSK), to treat asthma or chronic obstructive pulmonary disease (COPD).

Mylan plans to launch the product in the second half of February...

BCIQ Company Profiles

GSK plc

Mylan N.V.